EN
SINOVAC and Bio Farma Sign Strategic MoU to Advance Cooperation and Support Global Public Health
BEIJING, March 27, 2026 — SINOVAC and Bio Farma, Indonesia's state-owned pharmaceutical company, signed a strategic memorandum of understanding in Beijing on March 27, 2026, to expand cooperation in distribution, localization, and joint R&D.
The signing was witnessed by Budi Gunadi Sadikin, Minister of Health of the Republic of Indonesia, and Djauhari Oratmangun, Ambassador of Indonesia to China.
Back row, from left to right: dr. Irene M. Han, Deputy Ambassador of Indonesia to China; Yin Weidong, Executive Director & CEO of SINOVAC, Djauhari Oratmangun, Ambassador of Indonesia to China, Budi Gunadi Sadikin, Minister of Health of the Republic of Indonesia; Nizar Yamanie, Member of the Board of Bio Farma; Jeffri Susanto, Director and Chief Financial Officer of Bio Farma.
Front row, from left to right: Meng Weining, Vice President of Sinovac Holding Group; Yuliana Indriati, Director in charge of Research and Development at Bio Farma.
Speaking at the event, Minister Budi Gunadi Sadikin said SINOVAC had provided important support to Indonesia during the pandemic, laying a foundation of trust in the country, and noted that strengthening primary healthcare is a key priority as Indonesia’s healthcare system undergoes transformation.
He said SINOVAC and Bio Farma each bring distinct strengths and expressed confidence that the partnership would deliver tangible results. He added that, as two countries with large populations and facing shared health challenges, China and Indonesia should deepen cooperation across technology, industry and investment to expand access to high-quality public health products in developing countries.
Yin Weidong, Executive Director & CEO of SINOVAC, also attended a symposium for Chinese enterprises hosted in Beijing the same day by Indonesia’s Ministry of Health. Yin said SINOVAC and Bio Farma had built a strong partnership during the pandemic, laying a solid foundation for future cooperation. He added that the two sides would expand cooperation beyond existing products to include innovative vaccine R&D for the benefit of Indonesia and other countries.
Indonesia was the first country in the Asia-Pacific region to approve SINOVAC's EV71 vaccine, Inlive®, for the prevention of hand, foot and mouth disease (HFMD) caused by enterovirus type 71(EV71) in October 2024. SINOVAC’s hepatitis A vaccine, Healive®, and varicella vaccine have also been approved in Indonesia and have gained market recognition for their safety and efficacy.
Evidence-Based Product Development
SINOVAC remains committed to product quality backed by scientific innovation and robust clinical evidence.
At the end of 2025, SINOVAC’s varicella vaccine was approved in Indonesia. As the first and only varicella vaccine from China to have received World Health Organization (WHO) prequalification, it is developed using a proprietary human diploid cell line, manufactured under full-process B+A clean-area standards, and contains no antibiotics, gelatin, or human serum albumin. A recent clinical study published in Vaccines showed that the vaccine met the non-inferiority criterion for immunogenicity and demonstrated a better safety profile than the control vaccine. SINOVAC’s varicella vaccine has reached nearly 20 countries and regions, with nearly 30 million doses supplied globally.
SINOVAC’s hepatitis A vaccine, Healive®, was approved in Indonesia in early 2022. To date, it has been supplied to nearly 50 countries and regions, with more than 130 million doses distributed. A 15-year follow-up study showed that Healive® can provide protection for at least 30 years.
Supplying High-Quality Vaccines to Global Markets
Across Belt and Road partner markets, SINOVAC supports public health by supplying high-quality vaccines.
In early 2026, SINOVAC's hepatitis A vaccine exclusively won public-sector procurement projects in Oman and Chile. More recently, SINOVAC's inactivated poliomyelitis vaccine officially entered the African market and is currently being supplied to countries including Angola, Côte d’Ivoire, and Cameroon.
According to data from China's online customs statistics platform, the export value of China's human vaccines reached RMB 2.318 billion in 2025, up 53.51% year on year. Products including SINOVAC’s hepatitis A vaccine, influenza vaccine, varicella vaccine, and poliomyelitis vaccine accounted for more than 40% of the total.
The strategic cooperation between SINOVAC and Bio Farma will help expand access to high-quality public health products globally. From Southeast Asia to Africa, and from the Middle East to Latin America, SINOVAC will continue working with partners around the world to support global public health through high-quality vaccines and practical cooperation.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a global biopharmaceutical company headquartered in China. Guided by its mission to “Supply Vaccines to Eliminate Human Diseases,” the Company is dedicated to the research, development, manufacturing and supply of vaccines and related biological products, providing vaccine products and related solutions for disease prevention and control worldwide.
SINOVAC has a diversified vaccine portfolio across multiple disease areas, including influenza, viral hepatitis, varicella, hand, foot and mouth disease (HFMD), poliomyelitis, rabies, tetanus, and pneumococcal disease. Three of SINOVAC's vaccines have been prequalified by the World Health Organization: the inactivated hepatitis A vaccine Healive®, the Sabin-strain inactivated poliomyelitis vaccine (sIPV), and the live attenuated varicella vaccine.
SINOVAC has extensive experience in vaccine research, development and commercialization for emerging infectious diseases and public health emergencies. The Company initiated vaccine R&D in response to major public health threats, including SARS, H5N1, H1N1, and COVID-19, and developed the world's first inactivated SARS vaccine (with Phase I clinical trials completed), China's first inactivated pandemic influenza vaccine against H5N1 (Panflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the world's most widely used inactivated COVID-19 vaccine. Beyond its marketed portfolio, SINOVAC continues to advance its R&D pipeline, spanning combination vaccines, recombinant protein vaccines, mRNA technologies, antibody-based products, and other next-generation technologies and product platforms, while expanding its capabilities in disease prevention and biopharmaceuticals.
With a long-standing commitment to innovation and global health, SINOVAC continues to deepen collaboration with research institutions, international organizations, and local partners while expanding its global presence. Through technological collaboration, localized production, and industrial partnerships, the Company aims to improve access to high-quality vaccines across regions, better address local disease prevention and healthcare needs, and strengthen preparedness for future public health challenges.
For more information, please see the Company's website at www.sinovac.com.